{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"23.9"},{"groupId":"OG003","value":"16.7"},{"groupId":"OG004","value":"0.0"},{"groupId":"OG005","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR), determined by investigator assessment of radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1). CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \\<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.","groups":[{"description":"Participants with programmed cell death protein/programmed cell death ligand 1 (PD-1/PD-L1) relapsed melanoma (RM) received INCAGN01876 300 mg administered IV Q2W in combination with ipilimumab 1 mg/kg administered IV Q6W.","id":"OG000","title":"Phase 2 Group C2 PD-1/PD-L1 RM: INCAGN01876 300 mg + Ipilimumab 1 mg/kg"},{"description":"Participants with gastric cancer (GC) received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG001","title":"Phase 2 Group F GC: INCAGN01876 300 mg + Nivolumab 240 mg"},{"description":"Participants with squamous cell carcinoma of the head and neck (SCCHN) received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG002","title":"Phase 2 Group F SCCHN INCAGN01876 300 mg + Nivolumab 240 mg"},{"description":"Participants with cervical cancer (CC) received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG003","title":"Phase 2 Group F CC: INCAGN01876 300 mg + Nivolumab 240 mg"},{"description":"Participants with PD-1/PD-L1 relapsed melanoma received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG004","title":"Phase 2 Group F PD-1/PD-L1 RM: INCAGN01876 300 mg + Nivolumab 240 mg"},{"description":"Participants with gastric cancer, squamous cell carcinoma of the head and neck, cervical cancer, or PD-1/PD-L1 relapsed melanoma who had tumor lesions that were amenable to percutaneous biopsy received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG005","title":"Phase 2 Group F Biopsy: INCAGN01876 300 mg + Nivolumab 240 mg"}],"paramType":"NUMBER","populationDescription":"Phase 2 Response Evaluable Population: all participants enrolled in Phase 2 who received at least 1 dose of INCAGN01876, nivolumab, or ipilimumab; completed a Baseline scan; and met at least 1 of the following criteria: (a) ≥1 post-Baseline scan (b) the participant has been in the study for a minimum of 64 days of follow-up; or (c) the participant had discontinued from treatment","reportingStatus":"POSTED","timeFrame":"up to approximately 44.7 months","title":"Phase 2: Objective Response Rate (ORR) Per RECIST v1.1","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}